Attached files
| file | filename |
|---|---|
| 8-K - ZIOPHARM ONCOLOGY INC | v187115_8k.htm |
| EX-1.1 - ZIOPHARM ONCOLOGY INC | v187115_ex1-1.htm |
| EX-5.1 - ZIOPHARM ONCOLOGY INC | v187115_ex5-1.htm |
| EX-99.1 - ZIOPHARM ONCOLOGY INC | v187115_ex99-1.htm |
Exhibit
99.2
ZIOPHARM
prices common stock offering
NEW YORK, NY – May 27, 2010 -
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing of an
underwritten public offering of 7,000,000 shares of its common stock at a price
to the public of $5.00 per share. The net proceeds from the sale of the shares,
after underwriting discounts and commissions and estimated offering expenses,
are expected to be approximately $32.8 million. The offering is expected to
close on or about June 2, 2010, subject to customary closing
conditions.
Jefferies
& Company, Inc. is acting as the sole book-running manager for this
offering. The co-manager for this offering is JMP Securities LLC. The Company
has granted the underwriters a 30-day option to purchase up to an aggregate of
1,050,000 additional shares of common stock to cover over-allotments, if any.
The Company anticipates using the net proceeds from the offering for the overall
development of its drug candidates, including further expansion of the clinical
trial programs, and for general corporate and working capital
purposes.
The
securities described above are being offered by ZIOPHARM pursuant to a shelf
registration statement previously filed with and declared effective by the
Securities and Exchange Commission (the “SEC”) on May 13, 2010. Copies of the
final prospectus supplement relating to these securities, when available, may be
obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus
Department, 520 Madison Avenue, New York, NY, 10022 and at (888) 449-2342. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these securities
in any state or other jurisdiction which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities laws
of any such state or other jurisdiction.
About
ZIOPHARM Oncology, Inc.
ZIOPHARM
Oncology is a biopharmaceutical company engaged in the development and
commercialization of a diverse portfolio of cancer drugs. The Company is
currently focused on three clinical programs. Palifosfamide (ZymafosTM or
ZIO-201) references a novel composition (tris formulation) that is the
functional active metabolite of ifosfamide, a standard of care for treating
sarcoma, lymphoma, testicular, and other cancers. Darinaparsin (ZinaparTM or
ZIO-101) is a novel organic arsenic being developed for the treatment of various
hematologic and solid cancers. Indibulin (ZybulinTM or
ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and
cancer cell migration. ZIOPHARM’s operations are located in Boston, MA with an
executive office in New York.
Forward-Looking
Safe Harbor Statement
This
press release contains forward-looking statements that involve risks and
uncertainties, such as those, among others, relating to the Company’s
expectations regarding the completion, timing and size of its proposed public
offering. Among the factors that could cause actual results to differ
materially from those indicated in the forward-looking statements are risks and
uncertainties associated with market conditions and the satisfaction of
customary closing conditions related to the proposed offering, as well as risks
and uncertainties associated with the Company’s business and finances in
general, and the other risks described in the Company’s annual report on Form
10-K for the year ended December 31, 2009. The Company undertakes no obligation
to update the statements contained in this press release after the date
hereof.